To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR

Exclusion Criteria

• •1. Patients with proliferative diabetic retinopathy (diabetic retinopathy) or other causes of retinopathy.
• •2. Patients with uncontrolled diabetes or uncontrolled hypertension.
• •3. Patients with the following ocular diseases or surgical procedures:
• •\- Visual field defects, media opacity and ocular diseases other than diabetic retinopathywhich the investigator determines may affect the evaluation.
• •4. Patients who have received intravitreal and periocular steroid injections, intravitreal injection of anti-VEGF antibodies (anti-VEGF treatment), or laser photocoagulation within 12 weeks of the date of administration of the investigational drug
• •5. Patients taking Kallidinogenase, Vaccinium myrtillus extract, or Sulodexide
• •6. Patients who have experienced a cardiovascular event (unstable angina, myocardial infarction, transient ischemic attack, stroke, etc.) within 24 weeks prior to Visit 1 (participation is possible if the event occurred 24 weeks prior to Visit 1 and the patient is currently receiving medication in a stable condition)
• •7. Patients with severe renal impairment (renal failure requiring dialysis or (e.g., renal transplant)
• •8. Patients with a history of malignancy within the past 5 years from the time of screening. However, the following are eligible for clinical trial participation:
• •* More than 5 years have passed since the cancer was diagnosed as cured from the screening.
• •* Basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or other intraepithelial neoplasms
• •9. Pregnant or lactating women, or those who do not agree to use adequate contraception during the clinical trial.
• •10. Those who have received another investigational drug within 12 weeks prior to Visit 1
• •11. Those who are judged by the investigator to be unsuitable for clinical trial participation due to other clinically significant medical or psychiatric findings